EverGlade Insights Archives - Page 2 of 6 - EverGlade Consulting

EverGlade Insights

nucleic acid-based therapeutics

BARDA Announces Solicitation to Improve Nucleic Acid Platforms for Pre-Exposure Prophylaxis

Leave a Comment / BARDA, EverGlade Insights / By

PrEP_Solicitation_Nucleic_Acid_Platform_Approaches Overview of Solicitation The Biomedical Advanced Research and Development Authority (BARDA), partnered with the Vaccine Innovation and Therapeutics Accelerator Launchpad (VITAL), have announced a solicitation for proposals to address current limitations of long-acting nucleic acid-based platforms used as pre-exposure prophylaxis (PrEP) for seasonal respiratory viruses. The specific goals of these PrEP DEV awards include […]

BARDA Announces Solicitation to Improve Nucleic Acid Platforms for Pre-Exposure Prophylaxis Read More »

technology to identify novel antigens

DTRA MCDC RAIIC Funding Opportunity

Leave a Comment / DTRA, EverGlade Insights / By

Final-draft-SOO-RAIIC The Joint Science and Technology Office (JSTO) Defense Threat Reduction Agency (DTRA) has announced an upcoming funding opportunity for members of the Medical CBRN Defense Consortium (MCDC) to develop technologies that can accelerate the identification and immune profile of novel antigens in emerging infectious diseases (EID). JSTO intends to incorporate the final technology into

DTRA MCDC RAIIC Funding Opportunity Read More »

compact wearable vaccine monitoring

DTRA Issues Draft SOO for Continual Blood Sampling Technology

Leave a Comment / DTRA, EverGlade Insights / By

Final-Draft-SOO-IMMIR The Joint Science and Technology Office (JSTO) within the Defense Threat Reduction Agency (DTRA) has announced an upcoming funding opportunity for members of the Medical CBRN Defense Consortium (MCDC). The objective of the IMMIR solicitation is to develop innovative technologies for vaccine monitoring via a compact wearable device that can analyze minute blood samples.

DTRA Issues Draft SOO for Continual Blood Sampling Technology Read More »

Artificial Intelligence (AI) and Machine Learning (ML) innovations

DARPA Releases Strategic Catalyst Announcement for AI BTO

Leave a Comment / DARPA, EverGlade Insights, Time Sensitive / By

DARPA-SCA-24-01 The Biological Technologies Office (BTO) of the Defense Advanced Research Projects Agency (DARPA) recently released a Strategic Catalyst Announcement (SCA) titled AI BTO (Funding Opportunity Number: DARPA-SCA-24-01). AI BTO encourages participation by new or non-traditional proposers to leverage Artificial Intelligence (AI) and Machine Learning (ML) innovations for the BTO. Overview of AI BTO AI

DARPA Releases Strategic Catalyst Announcement for AI BTO Read More »

cancer moonshot

Cancer Moonshot and the ARPA-H Cancer Funding Landscape

Leave a Comment / ARPA-H, EverGlade Insights / By

Even with incredible scientific progress, cancer remains the second highest leading cause of death in the United States (U.S.) and one of the highest causes of death worldwide. To accelerate and bolster the great innovations made in therapeutics, diagnostics, and patient care, the Biden-Harris administration has reignited the Cancer Moonshot initiative. This program, introduced by

Cancer Moonshot and the ARPA-H Cancer Funding Landscape Read More »

mRNA infectious diseases vaccine development

BARDA Issues RPP for Rapid Pandemic Influenza and Emerging Infectious Disease Vaccine Development and Response Capability

Leave a Comment / BARDA, EverGlade Insights / By

24-08-mRNALongTerm_Final The Biomedical Advanced Research and Development Authority (BARDA) has released a Request for Project Proposals (RPP) aimed at vaccine development and response for emerging infectious diseases and rapid pandemic influenza. The RPP, numbered RRPV-24-08-mRNALongTerm, focuses on creating a lasting partnership that builds and maintains a robust mRNA preparedness and response system for pandemic influenza

BARDA Issues RPP for Rapid Pandemic Influenza and Emerging Infectious Disease Vaccine Development and Response Capability Read More »

medical countermeasures

DTRA Issues SOO for Broad-Spectrum Therapeutics

Leave a Comment / DTRA, EverGlade Insights / By

August-24-Broad-Spectrum-SOO The Defense Threat Reduction Agency (DTRA) has released a Statement of Objectives (SOO) to develop  prototype Medical Countermeasures (MCMs) aimed at addressing therapeutic indications of Warfigher exposure to viral and bacterial biothreat agents. Key Information and Deadlines The Project Agreement Holder must state if their proposal is for the solution of the objecties of

DTRA Issues SOO for Broad-Spectrum Therapeutics Read More »

cell therapies

ARPA-H Issues Draft Solicitation for Autologous Cell Therapy (ACT)

Leave a Comment / ARPA-H, EverGlade Insights, Time Sensitive / By

DECIDE_ET_Solicitation_DRAFT The Advanced Research Projects Agency for Health (ARPA-H) has introduced the Decentralized Engineering of Cells Informed by Dynamic Evidence (DECIDE) Exploration Topic (ET), representing a crucial initiative designed to revolutionize the production and validation of autologous cell therapies. This ET targets significant enhancements in the production processes at Academic Medical Centers (AMCs), focusing on

ARPA-H Issues Draft Solicitation for Autologous Cell Therapy (ACT) Read More »

biologics

BARDA Issues RPP for On-Demand Manufacturing

Leave a Comment / BARDA, EverGlade Insights / By

RPP-24-02-ODM The Biomedical Advanced Research and Development Authority (BARDA) has released an essential Request for Project Proposals (RPP) aimed at the preparation for and response to public health emergencies through On-Demand Manufacturing. The RPP, numbered 24-02-ODM, focuses advancing manufacturing technologies that will improve access and enable faster, cheaper, more rapid, and flexible production of vaccines

BARDA Issues RPP for On-Demand Manufacturing Read More »

cancer screening technologies

ARPA-H Announces RFP for Cancer Intervention and Detection

Leave a Comment / ARPA-H, EverGlade Insights, Time Sensitive / By

24-SOL-109+POSEIDON+DRAFT+ISO_9+AUG+24 The Advanced Research Projects Agency for Health (ARPA-H) has issued a Request for Proposals (RFP) for the POSEIDON program, a groundbreaking initiative aimed at advancing cancer screening technologies. The Platform Optimizing SynBio for Early Intervention and Detection in Oncology (POSEIDON) seeks to develop innovative, non-invasive tests that can detect multiple cancers at an early

ARPA-H Announces RFP for Cancer Intervention and Detection Read More »

host-directed-therapeutics

JPM & JPEO Issues RFI for Host-Directed Therapeutics for Prophylaxis

Leave a Comment / EverGlade Insights, JPEO / By

Evaluation Criteria White Paper Template W911SR-24-S-HDTX+RFI The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), along with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), invites stakeholders from industry, academia, and nonprofit sectors to submit white papers for the development and repurposing of host-directed therapeutics.

JPM & JPEO Issues RFI for Host-Directed Therapeutics for Prophylaxis Read More »

A closeup shot of a scientist conducting the gel electrophoresis biological process as part of coronavirus research

BARDA Announces Request for Project Proposals for Small Molecule Drugs

Leave a Comment / BARDA, EverGlade Insights / By

BARDA RRPV 24-03-SmMol The Biomedical Advanced Research and Development Authority (BARDA) has released a Request for Project Proposals (RPP) under the Rapid Response Partnership Vehicle (RRPV) for developing small molecule therapeutics aimed at COVID-19 Pre-exposure Prophylaxis (PrEP). This initiative enhances national health security by advancing medical countermeasures against SARS-CoV-2 and future health threats. BARDA’s call

BARDA Announces Request for Project Proposals for Small Molecule Drugs Read More »

Scroll to Top